68 related articles for article (PubMed ID: 25817992)
1. Interactions between Bcl-xl and its inhibitors: Insights into ligand design from molecular dynamics simulation.
Priya P; Maity A; Majumdar S; Ghosh Dastidar S
J Mol Graph Model; 2015 Jun; 59():1-13. PubMed ID: 25817992
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL.
Liu X; Beugelsdijk A; Chen J
Biophys J; 2015 Sep; 109(5):1049-57. PubMed ID: 26331262
[TBL] [Abstract][Full Text] [Related]
3. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the crucial molecular properties of a series of Benzothiazole Hydrazone inhibitors that targets anti-apoptotic Bcl-xL protein.
Marimuthu P; Balasubramanian PK; Singaravelu K
J Biomol Struct Dyn; 2018 Aug; 36(10):2654-2667. PubMed ID: 28793831
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
[TBL] [Abstract][Full Text] [Related]
6. Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1.
Maity A; Majumdar S; Ghosh Dastidar S
Comput Biol Chem; 2018 Dec; 77():17-27. PubMed ID: 30195235
[TBL] [Abstract][Full Text] [Related]
7. Cryptic-site binding mechanism of medium-sized Bcl-xL inhibiting compounds elucidated by McMD-based dynamic docking simulations.
Bekker GJ; Fukuda I; Higo J; Fukunishi Y; Kamiya N
Sci Rep; 2021 Mar; 11(1):5046. PubMed ID: 33658550
[TBL] [Abstract][Full Text] [Related]
8. Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach.
Wakui N; Yoshino R; Yasuo N; Ohue M; Sekijima M
J Mol Graph Model; 2018 Jan; 79():166-174. PubMed ID: 29197725
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Sampling of Intrinsic Structural Heterogeneity of the BH3-Only Protein Binding Interface of Bcl-xL.
Liu X; Jia Z; Chen J
J Phys Chem B; 2017 Oct; 121(39):9160-9168. PubMed ID: 28903561
[TBL] [Abstract][Full Text] [Related]
10. The long unstructured region of Bcl-xl modulates its structural dynamics.
Priya P; Maity A; Ghosh Dastidar S
Proteins; 2017 Aug; 85(8):1567-1579. PubMed ID: 28486788
[TBL] [Abstract][Full Text] [Related]
11. In silico SELEX screening and statistical analysis of newly designed 5mer peptide-aptamers as Bcl-xl inhibitors using the Taguchi method.
Poustforoosh A; Faramarz S; Nematollahi MH; Hashemipour H; Negahdaripour M; Pardakhty A
Comput Biol Med; 2022 Jul; 146():105632. PubMed ID: 35617726
[TBL] [Abstract][Full Text] [Related]
12. Energetic Fingerprinting of Ligand Binding to Paralogous Proteins: The Case of the Apoptotic Pathway.
Ivanov SM; Huber RG; Alibay I; Warwicker J; Bond PJ
J Chem Inf Model; 2019 Jan; 59(1):245-261. PubMed ID: 30582811
[TBL] [Abstract][Full Text] [Related]
13. Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.
Li H; Li C
J Comput Chem; 2010 Jul; 31(10):2014-22. PubMed ID: 20166125
[TBL] [Abstract][Full Text] [Related]
14. The N-terminus and alpha-5, alpha-6 helices of the pro-apoptotic protein Bax, modulate functional interactions with the anti-apoptotic protein Bcl-xL.
Parikh N; Koshy C; Dhayabaran V; Perumalsamy LR; Sowdhamini R; Sarin A
BMC Cell Biol; 2007 May; 8():16. PubMed ID: 17519046
[TBL] [Abstract][Full Text] [Related]
15. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
16. Target the More Druggable Protein States in a Highly Dynamic Protein--Protein Interaction System.
Guo Z; Thorarensen A; Che J; Xing L
J Chem Inf Model; 2016 Jan; 56(1):35-45. PubMed ID: 26650754
[TBL] [Abstract][Full Text] [Related]
17. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
Sleebs BE; Kersten WJ; Kulasegaram S; Nikolakopoulos G; Hatzis E; Moss RM; Parisot JP; Yang H; Czabotar PE; Fairlie WD; Lee EF; Adams JM; Chen L; van Delft MF; Lowes KN; Wei A; Huang DC; Colman PM; Street IP; Baell JB; Watson K; Lessene G
J Med Chem; 2013 Jul; 56(13):5514-40. PubMed ID: 23767404
[TBL] [Abstract][Full Text] [Related]
19. Conformational States of the Cytoprotective Protein Bcl-xL.
Ryzhov P; Tian Y; Yao Y; Bobkov AA; Im W; Marassi FM
Biophys J; 2020 Oct; 119(7):1324-1334. PubMed ID: 32888404
[TBL] [Abstract][Full Text] [Related]
20. Anti-apoptosis proteins Mcl-1 and Bcl-xL have different p53-binding profiles.
Yao H; Mi S; Gong W; Lin J; Xu N; Perrett S; Xia B; Wang J; Feng Y
Biochemistry; 2013 Sep; 52(37):6324-34. PubMed ID: 23977882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
